The value and impact of anti-Xa activity monitoring for prophylactic dose adjustment of low-molecular-weight heparin during pregnancy: A retrospective study

Blood Coagulation and Fibrinolysis

Volumn 28, Issue 3, 2017, Pages 199-204

  Boban, Ana ^a,b   Paulus, Samuel ^a   Lambert, Catherine ^a   Hermans, Cedric ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b KBC Zagreb   (Croatia)

Author keywords

anti Xa activity; low molecular weight heparin; monitoring; pregnancy; thrombophilia; venous thromboembolic disease

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ARTICLE; BODY MASS; DRUG MONITORING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OBESITY; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; WEIGHT GAIN; ADOLESCENT; THROMBOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; ANTICOAGULANTS; FACTOR XA INHIBITORS; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PREGNANCY; RETROSPECTIVE STUDIES; THROMBOSIS; YOUNG ADULT;

EID: 84973124328     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000573     Document Type: Article

References (37)

1. Bates M. Treatment and prophylaxis of venous thromboembolism during pregnancy. Thromb Res 2003; 108:97-106.
2. Brill-Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med 2000; 343:1439-1444.
3. De Stefano V,Martinelli I, Rossi E, Battaglioli T, Za T, Mannuccio MP, Leone G. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol 2006; 135:386-391.
4. Pabinger I,Grafenhofer H, Kaider A, Kyrle PA, Quehenberger P, Mannhalter C, Lechner K. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost 2005; 3:949-954.
5. Rodger MA, Phillips P, Kahn SR, Bates S, McDonald S, Khurana R, et al. Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thromb Haemost 2015; 113:212-216.
6. Bauersachs RM, Dudenhausen J, Faridi A, Fischer T, Fung S, Geisen U, et al. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost 2007; 98:1237-1245.
7. Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart JM, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:3147-3197.
8. Kujovich JL. Thrombophilia and pregnancy complications. Am J Obstet Gynecol 2004; 191:412-424.
9. Grandone E, Tomaiuolo M, Colaizzo D, Ames PR, Margaglione M. Role of thrombophilia in adverse obstetric outcomes and their prevention using antithrombotic therapy. Semin Thromb Hemost 2009; 35:630-643.
10. Tormene D, Grandone E, De Stefano V, Tosetto A, Palareti G, Margaglione M, et al. Obstetric complications and pregnancy-related venous thromboembolism: the effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation. Thromb Haemost 2012; 107:477-484.
11. Greer IA. Thrombophilia: implications for pregnancy outcome. Thromb Res 2003; 109:73-81.
12. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO, American College of Chest Physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e691S-736S.
13. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106:401-407.
14. Dimitrakakis C, Papageorgiou P, Papageorgiou I, Antzaklis A, Sakarelou N, Michalas S. Absence of transplacental passage of the low molecular weight heparin enoxaparin. Haemostasis 2000; 30:243-248.
15. Ensom MH, Stephenson MD. Low-molecular-weight heparins in pregnancy. Pharmacotherapy 1999; 19:1013-1025.
16. Walfisch A, Koren G. 'The warfarin window' in pregnancy: the importance of half-life. J Obstet Gynaecol Can 2010; 32:988-989.
17. Holzgreve W, Carey JC, Hall BD. Warfarin-induced fetal abnormalities. Lancet 1976; 2:914-915.
18. Guimicheva B, Czuprynska J, Arya R. The prevention of pregnancy-related venous thromboembolism. Br J Haematol 2014; 168:163-174.
19. Casele HL, Laifer SA, Woelkers DA, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999; 181:1113-1117.
20. Dulitzki M, Pauzner R, Langevitz P, Pras M, Many A, Schiff E. Lowmolecular-weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Obstet Gynecol 1996; 87:380-383.
21. Ellison J, Thomson AJ, Conkie JA, McCall F, Walker D, Greer A. Thromboprophylaxis following caesarean section - a comparison of the antithrombotic properties of three low molecular weight heparins-dalteparin, enoxaparin and tinzaparin. Thromb Haemost 2001; 86:1374-1378.
22. Lepercq J, Conard J, Borel-Derlon A, Darmon JY, Boudignat O, Francoual C, et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG 2001; 108:1134-1140.
23. Lebaudy C, Hulot JS, Amoura Z, Costedoat-Chalumeau N, Serreau R, Ankri A, et al. Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy. Clin Pharmacol Ther 2008; 84:370-377.
24. Gyamfi C, Cohen R, Desancho MT, Gaddipati S. Prophylactic dosing adjustment in pregnancy based upon measurements of antifactor Xa levels. J Matern Fetal Neonatal Med 2005; 18:329-331.
25. O'Connell MP, O'Leary M, MacKeogh L, Murphy K, Keane DP. Is the monitoring of anti-Xa activity necessary in pregnant women undergoing thromboprophylaxis? Eur J Obstet Gynecol Reprod Biol 2004; 114:12-14.
26. Rowan JA, McLintock C, Taylor RS, North RA. Prophylactic and therapeutic enoxaparin during pregnancy: indications, outcomes and monitoring. Aust N Z J Obstet Gynaecol 2003; 43:123-128.
27. Rey E, Rivard GE. Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. Int J Gynaecol Obstet 2000; 71:19-24.
28. Smith MP, Norris LA, Steer PJ, Savidge GF, Bonnar J. Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. Am J Obstet Gynecol 2004; 190:495-501.
29. Fox NS, Laughon SK, Bender SD, Saltzman DH, Rebarber A. Antifactor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis. Obstet Gynecol 2008; 112:884-889.
30. Shapiro NL, Kominiarek MA, Nutescu EA, Chevalier AB, Hibbard JU. Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: single-center experience. Pharmacotherapy 2011; 31:678-685.
31. Gibson PS, Newell K, Sam DX, Mansoor A, Jiang X, Tang S, Ross S. Weight-adjusted dosing of tinzaparin in pregnancy. Thromb Res 2013; 131:e71-e75.
32. Norris LA, Bonnar J, Smith MP, Steer PJ, Savidge G. Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study. ThrombHaemost 2004; 92:791-796.
33. Yinon Y, Siu SC, Warshafsky C, Maxwell C, McLeod A, Colman JM. Use of low molecular weight heparin in pregnant women with mechanical heart valves. Am J Cardiol 2009; 104:1259-1263.
34. Abildgaard U, Sandset PM, Hammerstrøm J, Gjestvang FT, Tveit A. Management of pregnant women with mechanical heart valve prosthesis: thromboprophylaxis with low molecular weight heparin. Thromb Res 2009; 124:262-267.
35. Oran B, Lee-Parritz A, Ansell J. Low molecular weight heparin for the prophylaxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancy. Thromb Haemost 2004; 92:747-751.
36. Berresheim M, Wilkie J, Nerenberg KA, Ibrahim Q, Bungard TJ. A case series of LMWH use in pregnancy: Should trough anti-Xa levels guide dosing? Thromb Res 2014; 134:1234-1240.
37. Patel JP, Green B, Patel RK, Marsh MS, Davies JG, Arya R. Population pharmacokinetics of enoxaparin during the antenatal period. Circulation 2013; 128:1462-1469.